The Institutional Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran, approved the study protocol. The study was explained thoroughly to participants, and an informed written consent was obtained from all patients. Corresponding IRCT number for the current study is IRCT201209165140N5. One hundred and twenty subjects (60 opium abusers and 60 without a history of opium abuse) American Society of Anesthesiologist (ASA) physical status class I and II, male, current smokers, aged between 18-60, scheduled for elective upper limb orthopedic surgery under supraclavicular nerve block in Shariati Hospital affiliated to Tehran University of Medical Sciences were enrolled in this randomized, double-blinded clinical trial.
Chronic opium abuse was defined as recurrent and continuous daily consumption of 1 - 2 grams of opium via inhalation route for at least one year without a cessation until the day of operation based on patients' report. To rule out opium use in control groups and confirm opium use in the study group, in all patients, a rapid opiate urine test was performed. None of the patients had any intention to stop opium use before the operation and all the patients continued using their typical inhaled opium until the day of operation in the preoperative visit. Patients were given their daily doses of inhaled opium on the day of operation.
Patients with any contraindications to supraclavicular nerve block, patients with addiction to any substance other than opium and cigarettes, and patients with known history of cardiac, respiratory, or psychological diseases were not entered in the study. All required drugs were prepared by an anesthetist not involved in the administration or observation of patients; thus, both anesthesiologist and patients were blinded to group assignment. The anesthesiologist who performed the nerve block and documented sensory levels was also blinded to patient groups.
The patients were first assigned to two different groups based on opium abuse history, then patients in each group were randomly assigned to either bupivacaine plus saline or bupivacaine plus sufentanil based on a computer generated list. The study groups were defined as follows: Group A (n = 30) had no history of chronic opium use and received 30 mL hyperbaric bupivacaine along with 2 mL saline as placebo. Group B (n = 30) had no history of opium use and received 30 mL hyperbaric bupivacaine along with 2 mL sufentanil (10 µg, n = 30). Group C (n = 30) had a positive history of chronic opium use and received 30 mL hyperbaric bupivacaine along with 2 mL saline as placebo. Lastly, group D, (n = 30) had a positive history of chronic opium abuse and received 30 mL hyperbaric bupivacaine along with 2 mL sufentanil (10 µg). The consort flow diagram is shown in
Figure 1.
The Consort Flow Diagram of the Clinical Trial
On arrival to the operating room, standard monitoring was applied (pulse oximetry, noninvasive arterial blood pressure and electrocardiography). Supplemental oxygen was delivered via face mask at a rate of 3 - 5 lit/minute. After, an 18-gauge IV catheter was inserted in a peripheral vein on the dorsum of non-injured hand and 1 mg of midazolam was administered.
To perform supraclavicular block, patients were positioned supine, with the head turned to contralateral side, rotated to an angle of 45 degree from midline and the arm was placed at the side. After skin sterilization and preparation, the probe was covered with sterile dressing. The subclavian artery was palpated and visualized using SonoAce X8 ultrasound machine (Samsung Medison, South Korea) with a linear probe with a frequency range of 5-12 MHz. Then the skin was anesthetized by subcutaneous injection of 3 mL 1% lidocaine. Next, under ultrasonographic guidance, a 22-gauge, 5 cm insulated Sprotte needle was advanced along the long axis of the probe from lateral to medial direction, the supraclavicular plexus sheath was penetrated by an in-plane technique. When the needle reached the brachial plexus cluster, correct positioning of needle tip was demonstrated with ultrasound. For precise localization of the nerve cluster, using Plexygon nerve stimulator (Vygon Vet, UK), stimulation began at a frequency of 1 Hz, with a duration of 0.1 ms. The intensity of stimulating current was initially set to deliver 1 - 2 mA and was then gradually decreased. The correct site of needle was confirmed when output current 0.2 - 0.4 mA still elicited a distal motor response. Subsequently, the needle was redirected and advanced to the most superficial portion formed by brachial plexus trunks and divisions in the lateral side of cluster and the remaining 15 mL local anesthetic was injected after negative aspiration was performed. During injection of every 5.0 - 6.0 mL, negative aspiration was performed to avoid intravascular injection. Subsequently, the needle was redirected and advanced to the most superficial portion.
Preoperative pain management protocol was the same for all patients. The patients received intermittent (every 6 hours) intravenous Apotel (15 mg/Kg) (Intravenous Paracetamol 1000 mg/6.7 mL, UNI-PHARMA S.A.) if the VAS score for pain was higher than three. Diclofenac suppository was administered to patients who had pain despite intravenous Apotel administration. In the case of block failure of any nerve distributions (i.e. if the patient felt pain in those regions), the patient was excluded from the study, even when the block was adequate to perform the operation.
Sensory and motor block was checked continuously after completion of injection until complete sensory and motor block and every 15 minutes following the end of operation. A pinprick test was used and compared with the same stimulation on the contralateral hand. The sensory block was assessed by a verbal rating scale from 100% (normal sensation) to 0 (no sensation). The motor block was evaluated by performing thumb abduction (radial nerve), thumb adduction (ulnar nerve), thumb opposition (median nerve) and elbow flexion (musculocutaneous nerve). A modification of the Lovett rating scale was used to assess the motor block as follows: 0 (complete paralysis), 1 (almost complete paralysis), 2 (pronounced mobility impairment), 3 (slightly impaired mobility), 4 (pronounced reduction of muscular force), 5 (slightly reduced muscular force) and 6 (normal muscle force).
The sensory and motor block onset time was defined as the time between the end of the last injection and complete absence of pinprick response and complete paralysis (Lovett rating scale = 0) in all nerve distributions. The duration of sensory block was defined as the time interval between complete sensory block (complete absence of pinprick response) and the first postoperative pain. The motor block duration time was defined as the time interval between complete paralysis (Lovett rating scale = 0) and complete recovery (Lovett rating scale = 6). It was estimated that a minimum of 30 patients in each group would be required to have a 95% power of detecting a 50-minute sensory block time difference at a significance level of 0.05. Normal distribution of age, height, weight, surgery time, onset time and duration of sensory and motor block were evaluated using the Kolmogorov-Smirnov test. All tested variables followed a normal distribution. Height, weight, age, onset time, operation time and duration of sensory and motor block were compared between the four groups by one-way analysis of variance (ANOVA) and Tukey post hoc tests. The ASA physical status and gender were compared using chi-square test and Fisher’s exact test. Two-tailed P < 0.05 was considered significant.